Please try another search
RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair, and regeneration. The company is developing RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease, or other pathology; RGN-352, an injectable formulation for the treatment of cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications; and RGN-137, a topical gel for the treatment of dermal wounds and reduction of scar tissue. It has strategic partnerships with Lee’s Pharmaceutical Group and HLB Therapeutics. The company was formerly known as Alpha 1 Biomedicals, Inc. and changed its name to RegeneRx Biopharmaceuticals, Inc. in 2000. RegeneRx Biopharmaceuticals, Inc. was incorporated in 1982 and is based in Rockville, Maryland.
Name | Age | Since | Title |
---|---|---|---|
Allan L. Goldstein | 86 | 1982 | Founder, Chairman, Chief Scientific Officer & Chairman of Scientific Advisor Board |
Gabriel Sosne | - | - | Scientific Advisory Board Member |
Jo-David Fine | - | - | Scientific Advisory Board Member |
J. J. Finkelstein | 72 | 2002 | President, CEO & Director |
R. Donald Elsey | 70 | 2010 | Independent Director |
Ewald Hannappel | - | - | Scientific Advisory Board Member |
Mauro Bove | 69 | 2004 | Independent Director |
Barrett Katz | 74 | - | Scientific Advisory Board Member |
Joseph Claudius McNay | 90 | 2002 | Independent Director |
Hynda K. Kleinman | - | - | Scientific Advisory Board Member |
Deepak Srivastava | - | - | Scientific Advisory Board Member |
Alessandro Noseda | 65 | 2019 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review